MRK ▲ +0.3% - Merck & Co., Inc. $MRK U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) 25-SEP-2026 06:45 AM ET